Pramlintide Acetate

正文共： 3000字 3图 预计阅读时间： 8分钟 Amylin作为针对肥胖和超重的新药研发热门靶点之一，正吸引着全球制药行业的高度关注。MNC公司、欧美biotech公司、欧美基金公司委托药时代帮助寻找靶向Amylin受体的小分子新药产品或可口服的多肽产品等其他分子实体，目前所处阶段最好是PCC已经确定。 我们诚挚邀请感兴趣的公司推荐更多靶向Amylin受体的小分子新药产品或可口服的多肽产品等其他分子实体。 如果您有相关产品或信息，请速速联系药时代BD团队，邮箱：BD@drugtimes.cn 让我们共同推动Amylin靶点新药的研发，为肥胖和超重患者带来更多的治疗选择。 以下内容仅供参考，欢迎批评指正！衷心感谢！~ Amylin作为肥胖新药研发的靶点的作用机理 Amylin（胰淀素）是一种由37个氨基酸组成的多肽激素，由胰岛β细胞分泌，与胰岛素一起在餐后被释放到血液中。它在代谢调节中发挥重要作用，特别是在控制食欲和能量平衡方面。以下是Amylin作为肥胖新药研发靶点的主要作用机理： 抑制食欲： Amylin通过作用于大脑中的食欲调节中枢，减少食欲，增加饱腹感，从而减少食物摄入。这种作用机制有助于控制过度饮食，减少能量摄入。 延缓胃排空： Amylin能够抑制肠胃蠕动，延缓胃排空速度。这不仅增加了饱腹感，还减少了食物在胃中的停留时间，从而进一步控制食物摄入。 抑制胰高血糖素分泌： Amylin可以抑制胰高血糖素的分泌，从而减少肝脏中的葡萄糖生成，帮助调节血糖水平。这一机制对于控制餐后血糖升高尤为重要。 增加能量代谢： Amylin通过多种机制增加机体的能量代谢，包括促进脂肪氧化和减少脂肪组织重量。这有助于减少体内脂肪积累，从而达到减重的效果。 改善瘦素应答： Amylin可以改善瘦素的应答，增强瘦素在调节能量平衡和体重管理中的作用。瘦素是一种重要的食欲调节激素，通过改善瘦素应答，Amylin进一步增强了减重效果。 抑制胃酸分泌： Amylin能够抑制胃酸分泌，减少胃部不适，从而间接影响食欲和食物摄入。这一机制有助于减少因胃部不适引起的过度进食。Amylin的代谢调节功能主要通过胰淀素受体（Amylin receptors, AMYRs）介导完成。胰淀素受体是一类特殊的蛋白异二聚体，由降钙素受体（Calcitonin receptor, CTR）和受体活性修饰蛋白（Receptor-Activity Modifying Protein, RAMPs）形成。RAMPs分为三种亚型：RAMP1、RAMP2和RAMP3，分别与CTR形成AMY1、AMY2和AMY3三种亚型的受体。临床应用主要包括以下方面。 Pramlintide： Pramlintide是首个获批用于糖尿病管理的合成胰淀素类似物，具有类似于GLP-1受体激动剂的减肥效果。它通过模拟天然胰淀素的作用机制，参与调控食欲、减缓胃排空速度以及改善血糖控制。然而，其疗效有限且与恶心和低血糖等副作用相关，妨碍其在临床上的广泛使用。 Cagrilintide： Cagrilintide是一种新型长效胰淀素类似物，在二期临床试验中，每周一次给药方案下的Cagrilintide呈现出剂量依赖性的体重减轻作用，其效果介于6%至10.8%之间。相比之下，同样为3毫克剂量的利拉鲁肽带来的体重减轻为9%，而安慰剂组则只有3%的减轻幅度。 Amycretin： Amycretin是一款GLP-1R和胰淀素受体的长效协同激动剂，正在开发皮下注射（每周一次）和口服（每天一次）两种剂型，目前拟开发适应症为肥胖。一项包含16位患者的口服Amycretin小型1期试验表明，患者在接受治疗12周后其体重下降幅度达13.1%，相较之下，安慰剂组患者的体重下降幅度仅为1.1%。此外，Amycretin展现良好的药代动力学特性，以及与其所开发的GLP-1类疗法类似的良好安全性、耐受性以及不良反应。Amylin通过多种机制调节食欲、延缓胃排空、抑制胰高血糖素分泌、增加能量代谢和改善瘦素应答，从而在肥胖和糖尿病治疗中发挥重要作用。随着对Amylin受体的深入研究，靶向Amylin的新药研发正在快速推进，未来有望为肥胖和糖尿病患者提供更有效的治疗选择。 Amylin新药相关交易简介 1. 百时美施贵宝收购Amylin Pharmaceuticals 2012年，百时美施贵宝以50亿美元的价格收购了Amylin Pharmaceuticals。Amylin Pharmaceuticals是一家专注于糖尿病诊断和治疗产品的生物制药公司，其新药Bydureon（每周注射一次的糖尿病治疗用药）具有年销售额15亿美元的潜力。2. 诺和诺德的Amycretin 2024年3月7日，诺和诺德在投资者日活动上汇报了其减重管线的布局和进展，特别引人注目的是口服Amycretin。这是一种GLP-1R和Amylin受体激动剂，一期临床中治疗12周减重13.1%，远优于司美格鲁肽治疗12周减重6%的效果。这一数据推动了诺和诺德股价盘前涨近6%，市值逼近6000亿美元。3. Zealand Pharma的Petrelintide 2024年6月21日，丹麦制药公司Zealand Pharma公布了其减肥注射剂Petrelintide的积极试验结果，引发市场热烈反响，股价飙升20%。Petrelintide属于长效Amylin类药物，在减重和稳定血糖方面显示出良好前景。1B期MAD试验结果显示，接受高剂量Petrelintide治疗的参与者平均体重下降了8.6%，而安慰剂组体重仅下降了1.7%。4. 礼来与KeyBioscience的合作 2024年10月10日，瑞士KeyBioscience和礼来公司宣布扩大在开发双胰淀素（Amylin）和降钙素（Calcitonin）受体激动剂（DACRA）方面的合作。DACRA是一种新型的双受体激动剂，旨在通过双重机制增强食欲抑制，实现更好的减重效果。5. 先为达生物与Verdiva Bio的合作 2025年1月10日，先为达生物宣布与Verdiva Bio达成了一项全球开发和商业化许可与合作协议，涉及每周一次口服GLP-1受体激动剂伊诺格鲁肽等3款产品组合，总金额高达24.7亿美元。Verdiva Bio是一家专注于开发针对肥胖和其他心血管代谢紊乱的创新疗法的公司，刚刚完成4.11亿美元A轮融资。此次合作的产品组合包括： 口服伊诺格鲁肽（Ecnoglutide Oral, XW004）：处于II期临床试验准备阶段的潜在同类首创的每周一次口服GLP-1受体激动剂。 口服胰淀素受体激动剂（Amylin RA）：处于临床前阶段的潜在同类首创的每周一次口服胰淀素受体激动剂，可用作单药治疗或与GLP-1受体激动剂联合使用。 皮下注射胰淀素受体激动剂（Amylin RA）：处于临床前阶段的潜在同类最佳的长效皮下注射胰淀素受体激动剂，可用作单药治疗或与GLP-1受体激动剂联合使用。 这些交易和合作表明，Amylin作为肥胖和糖尿病治疗的新靶点，正在吸引越来越多的制药公司的关注和投资。通过这些合作和收购，制药公司希望利用Amylin的多重机制，开发出更有效的减重和降糖药物，满足市场对创新疗法的迫切需求。 如果您有相关产品或信息，请速速联系药时代BD团队，邮箱：BD@drugtimes.cn 让我们共同推动Amylin靶点新药的研发，为肥胖和超重患者带来更多的治疗选择。 参考资料： 各家公司官网 药时代数据库 其它公开信息 推荐阅读 美国上市公司寻找创新性ADC、双抗，您感兴趣吗？| 药时代BD项目 2024-07-25 诺和、礼来看好的ADC payload，您感兴趣吗？| 药时代BD项目 2024-07-22 药时代BD-030项目 | IND ready阶段月制剂减重药物GDF15融合蛋白寻求合作 2024-06-25 药时代BD需求 | 顶级MNC寻找优质项目：炎症性肠病、哮喘、慢阻肺、特发性肺间质纤维化 2024-05-03 版权声明/免责声明 本文为汇编文章。 本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。 文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。 如有任何问题，请与我们联系。 衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击这里，查看更多精彩内容！

Partnership will leverage Iktos's AI-enabled drug discovery platform and Cube Biotech's advanced protein technologies to develop novel agonists of the Amylin Receptor PARIS and MONHEIM, Germany, Jan. 10, 2025 /PRNewswire/ -- Iktos, a leader in Artificial Intelligence (AI) and Robotics for drug design, and Cube Biotech, a pioneer in membrane protein production and purification technologies, today announced a strategic collaboration to discover novel small molecule agonists of the Amylin Receptor. The partnership combines Iktos' generative AI-driven drug discovery and robotic synthesis platform with Cube Biotech's advanced native membrane protein technology NativeMPTM, as well as their purification and biophysical assay expertise, to accelerate the development of breakthrough therapies. This paves the way for a joint collaborative offering directed towards pharmaceutical companies, combining the strengths of both platforms to undertake their most challenging drug discovery programs. Amylin receptor agonists hold significant promise for addressing unmet medical needs in cardiometabolic disorders, including obesity, diabetes, and metabolic dysfunction-associated steatotic hepatitis (MASH). The Amylin Receptor regulates appetite and satiety, making it a compelling target for obesity, which affects over one-third of the global population. Existing GLP-1 receptor agonist therapies like semaglutide or the peptide Amylin analogue Pramlintide have limited impact due to high costs, accessibility, and undesirable side effects. Orally administered novel small molecule agonists of the Amylin receptor could overcome these barriers, offering scalable and effective treatments and providing better management for the growing obesity epidemic and its comorbidities. However, the receptor's structural and biological complexity has long posed challenges for discovering viable low-molecular-weight modulators. "By tackling one of the most pressing unmet needs in cardiometabolic disorders, our partnership with Cube Biotech aims to discover improved treatments for patients affected by obesity, diabetes, and related conditions," said Yann Gaston-Mathé, Co-founder and CEO of Iktos. "We are excited to add the Amylin Receptor to our pipeline as this complex, yet promising target demands innovation at every stage. We see this collaboration as a foundation for future initiatives, extending the reach of our combined platform to address the most challenging membrane targets for the benefit of our pharma partners." Iktos has developed a cutting-edge 3D generative chemistry technology for structure-guided de novo design that natively accounts for protein flexibility during molecule optimization—a key advantage over models like AlphaFold, which can only be applied post-molecule generation. Cube Biotech has developed a world-leading protein production platform, based on NativeMP™ technology, which preserves the natural configuration of membrane proteins - a key advantage in accessing biologically active drug targets for testing. The company's native protein stabilization technology enhances the reliability and precision of functional assays, structural insights, and downstream applications. "Amylin Receptor is a challenging but highly promising target for metabolic disorders", said Dr. Barbara Maertens, Co-founder and COO of Cube Biotech. "Through our collaboration with Iktos, we aim to leverage our advanced protein stabilization and structural analysis technologies to validate and accelerate the discovery of novel small molecule agonists. Together, we are setting a new standard for efficiency and innovation in drug discovery." These integrated technologies endeavor to overcome longstanding inefficiencies in drug discovery, shortening timelines, improving success rates, and unlocking new possibilities for targeting complex and historically elusive membrane proteins, such as G-protein coupled receptors (GPCRs), membrane transporters, ion channels, and others. About Iktos Iktos is a leader in artificial intelligence and robotic solutions applied to research in medicinal chemistry and new drug design. Iktos' proprietary and innovative generative AI solution enables the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos has also developed Iktos Robotics, a unique AI-driven synthesis automation platform that dramatically accelerates the Design-Make-Test-Analyze cycle in drug discovery and is developing its own pipeline of drug candidates targeting oncology and auto-immune and inflammatory diseases. In March 2023, Iktos completed a 15.5M€ Series A financing round co-led by M Ventures and Debiopharm Innovation with contribution by Omnes Capital. In July 2024, Iktos announced the acquisition of Synsight, thereby complementing its Chemistry AI platform with a groundbreaking biology platform for the discovery of new drugs targeting Protein-Protein Interactions (PPI) and RNA-Protein Interactions (RPI). About Cube Biotech Cube Biotech is a leader in membrane protein production, purification, and characterization technologies. With proprietary copolymer-based solutions that maintain biological integrity in native-like protein states, Cube Biotech enables groundbreaking research in challenging drug targets, including membrane receptors, protein co-expressions, and even larger complexes. The company's expertise in assay development, biophysical characterization, and structural resolution supports efficient drug discovery workflows across the pharmaceutical and biotechnical industries. Additionally, an extensive purification resin and magnetic bead portfolio for affinity chromatography and efficient protein purification is manufactured in-house at high quality. For more information, visit . Media Contact: Eleonora Echegaray P: 35 823189279 E: [email protected] SOURCE Iktos WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED